MedTrace Logo

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NCT06975644 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-05-22

No results posted yet for this study

Summary

Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)

Conditions

  • Triple-Negative Breast Cancer (TNBC)
  • Neoadjuvant Chemotherapy
  • Chemotherapy Effects

Interventions

DRUG

nab-paclitaxel, carboplatin, and bemotuzumab

nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W

DRUG

epirubicin, cyclophosphamide, and bemotuzumab

epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W

Sponsors & Collaborators

  • Zhejiang Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Xuli Meng · Zhejiang Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-09-01
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975644 on ClinicalTrials.gov